364 related articles for article (PubMed ID: 28332824)
1. Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease.
Nam MH; Park M; Park H; Kim Y; Yoon S; Sawant VS; Choi JW; Park JH; Park KD; Min SJ; Lee CJ; Choo H
ACS Chem Neurosci; 2017 Jul; 8(7):1519-1529. PubMed ID: 28332824
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, monoamine oxidase inhibitory activity and computational study of novel isoxazole derivatives as potential antiparkinson agents.
Agrawal N; Mishra P
Comput Biol Chem; 2019 Apr; 79():63-72. PubMed ID: 30731360
[TBL] [Abstract][Full Text] [Related]
3. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
4. A novel selective MAO-B inhibitor with neuroprotective and anti-Parkinsonian properties.
Chan HH; Tse MK; Kumar S; Zhuo L
Eur J Pharmacol; 2018 Jan; 818():254-262. PubMed ID: 29050969
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotection by Paeoniflorin in the MPTP mouse model of Parkinson's disease.
Zheng M; Liu C; Fan Y; Yan P; Shi D; Zhang Y
Neuropharmacology; 2017 Apr; 116():412-420. PubMed ID: 28093210
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 3,4-dichloro-N-(1H-indol-5-yl)benzamide: A highly potent, selective, and competitive hMAO-B inhibitor with high BBB permeability profile and neuroprotective action.
Elkamhawy A; Kim HJ; Elsherbeny MH; Paik S; Park JH; Gotina L; Abdellattif MH; Gouda NA; Cho J; Lee K; Nim Pae A; Park KD; Roh EJ
Bioorg Chem; 2021 Nov; 116():105352. PubMed ID: 34562673
[TBL] [Abstract][Full Text] [Related]
7. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
Waldmeier PC; Spooren WP; Hengerer B
Naunyn Schmiedebergs Arch Pharmacol; 2000 Dec; 362(6):526-37. PubMed ID: 11138845
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies.
Elkamhawy A; Paik S; Park JH; Kim HJ; Hassan AHE; Lee K; Park KD; Roh EJ
Bioorg Chem; 2021 Oct; 115():105233. PubMed ID: 34390968
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
Yeon SK; Choi JW; Park JH; Lee YR; Kim HJ; Shin SJ; Jang BK; Kim S; Bahn YS; Han G; Lee YS; Pae AN; Park KD
Bioorg Med Chem; 2018 Jan; 26(1):232-244. PubMed ID: 29198609
[TBL] [Abstract][Full Text] [Related]
10. Role of nitric oxide synthase against MPTP neurotoxicity in mice.
Kurosaki R; Muramatsu Y; Michimata M; Matsubara M; Kato H; Imai Y; Itoyama Y; Araki T
Neurol Res; 2002 Oct; 24(7):655-62. PubMed ID: 12392201
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.
Liu Z; Cai W; Lang M; Yan R; Li Z; Zhang G; Yu P; Wang Y; Sun Y; Zhang Z
J Mol Neurosci; 2017 Apr; 61(4):498-510. PubMed ID: 28144826
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of transcription factor SP1 produces neuroprotective effects through decreasing MAO B activity in MPTP/MPP
Yao L; Dai X; Sun Y; Wang Y; Yang Q; Chen X; Liu Y; Zhang L; Xie W; Liu J
J Neurosci Res; 2018 Oct; 96(10):1663-1676. PubMed ID: 30004136
[TBL] [Abstract][Full Text] [Related]
13. Hydroxytyrosol as anti-parkinsonian molecule: Assessment using in-silico and MPTP-induced Parkinson's disease model.
Pathania A; Kumar R; Sandhir R
Biomed Pharmacother; 2021 Jul; 139():111525. PubMed ID: 33882412
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, Biological Evaluation and Molecular Modeling Studies of Propargyl-Containing 2,4,6-Trisubstituted Pyrimidine Derivatives as Potential Anti-Parkinson Agents.
Kumar B; Kumar M; Dwivedi AR; Kumar V
ChemMedChem; 2018 Apr; 13(7):705-712. PubMed ID: 29534334
[TBL] [Abstract][Full Text] [Related]
15. Different susceptibility to 1-methyl-4-phenylpyridium (MPP(+))-induced nigro-striatal dopaminergic cell loss between C57BL/6 and BALB/c mice is not related to the difference of monoamine oxidase-B (MAO-B).
Ito T; Suzuki K; Uchida K; Nakayama H
Exp Toxicol Pathol; 2013 Jan; 65(1-2):153-8. PubMed ID: 21855308
[TBL] [Abstract][Full Text] [Related]
16. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor.
Sagi Y; Weinstock M; Youdim MB
J Neurochem; 2003 Jul; 86(2):290-7. PubMed ID: 12871570
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel 2,3-dihydro-1H-inden-1-amine derivatives as selective monoamine oxidase B inhibitors.
Li S; Lv X; Cheng K; Tian Y; Huang X; Kong H; Duan Y; Han J; Liao C; Xie Z
Bioorg Med Chem Lett; 2019 May; 29(9):1090-1093. PubMed ID: 30833108
[TBL] [Abstract][Full Text] [Related]
19. Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
Tao D; Wang Y; Bao XQ; Yang BB; Gao F; Wang L; Zhang D; Li L
Eur J Med Chem; 2019 Jul; 173():203-212. PubMed ID: 31005056
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of some novel 2-substituted benzothiazole derivatives containing benzylamine moiety as monoamine oxidase inhibitory agents.
Kaya B; Sağlık BN; Levent S; Özkay Y; Kaplancıklı ZA
J Enzyme Inhib Med Chem; 2016 Dec; 31(6):1654-61. PubMed ID: 27028260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
